Otsuka is voluntarily recalling certain lots of ABILIFY® (aripiprazole) Tablets due to cross-contamination from extremely small amounts of another active pharmaceutical ingredient previously manufactured on the same equipment. Based on sample testing performed, there is no material patient risk associated with the trace level of contamination found. The voluntary recall has been initiated by Otsuka out of an abundance of caution, with the knowledge of the U.S. Food and Drug Administration. This recall is limited to the United States.

Consumers who have a product that is being recalled and who have concerns, should consult with their healthcare provider or pharmacy. Adverse reactions or quality problems experienced with the use of this product should be reported.

Otsuka America Pharmaceutical, Inc. can be reached by phone at 1-833-468-7852 Monday – Friday, 9 a.m. – 5 p.m. Eastern Time or by email: or The FDA's MedWatch Adverse Event Reporting program can be reached either online or by phone. To complete and submit the report Online: or call 1-800-332-1088.

Read more here:

April 2024 01US24EBC0008

Our Impact

For more than 100 years, our people have been passionate about helping others. Otsuka’s approach to Social Impact is grounded in the idea of creating better health worldwide by tackling the issues that only Otsuka can solve.

We envision a world where everyone can access the healthcare they need. A place where every person living with a mental illness or other chronic disease feels supported and empowered to live life on their terms. It is our privilege to walk alongside our communities as allies and advocates to overcome barriers and reduce inequities.

Our promise is to invest in products, programs, policies, and advocacy efforts that help remove stigma and discrimination, increase access to care, and address social determinants of health. This is not just our promise, it is our passion.